Tempus AI (NASDAQ:TEM – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $85.00 price objective on the stock. HC Wainwright‘s price objective suggests a potential upside of 57.48% from the stock’s current price.
A number of other brokerages also recently issued reports on TEM. Weiss Ratings upgraded Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. BTIG Research increased their price objective on Tempus AI from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, November 3rd. Robert W. Baird increased their price objective on Tempus AI from $85.00 to $92.00 and gave the stock an “outperform” rating in a report on Tuesday, November 3rd. Roth Capital began coverage on Tempus AI in a research report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price objective on the stock. Finally, Stifel Nicolaus reduced their target price on Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a research note on Monday, August 3rd. Eleven research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $79.37.
Get Our Latest Stock Analysis on Tempus AI
Tempus AI Stock Performance
Tempus AI (NASDAQ:TEM – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The company had revenue of $411.54 million during the quarter, compared to analyst estimates of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. Tempus AI’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.46) earnings per share. As a group, equities analysts anticipate that Tempus AI will post -1.20 EPS for the current year.
Insiders Place Their Bets
In other news, CEO Eric P. Lefkofsky sold 250,000 shares of Tempus AI stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $70.36, for a total transaction of $17,590,000.00. Following the sale, the chief executive officer owned 50,000 shares of the company’s stock, valued at approximately $3,518,000. The trade was a 83.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 10,247 shares of Tempus AI stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $63.02, for a total transaction of $645,765.94. Following the sale, the chief executive officer directly owned 652,216 shares in the company, valued at $41,102,652.32. The trade was a 1.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 1,006,807 shares of company stock worth $73,914,365. Company insiders own 24.26% of the company’s stock.
Hedge Funds Weigh In On Tempus AI
A number of institutional investors have recently bought and sold shares of the stock. Pictet Asset Management Holding SA grew its holdings in Tempus AI by 2,965.7% in the third quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock worth $41,233,000 after purchasing an additional 486,493 shares during the period. First Trust Advisors LP increased its stake in shares of Tempus AI by 90.3% during the third quarter. First Trust Advisors LP now owns 456,624 shares of the company’s stock valued at $37,397,000 after purchasing an additional 216,692 shares in the last quarter. Eagle Health Investments LP bought a new position in shares of Tempus AI during the first quarter valued at approximately $11,588,000. Swiss National Bank lifted its holdings in shares of Tempus AI by 0.3% during the first quarter. Swiss National Bank now owns 183,500 shares of the company’s stock valued at $8,298,000 after purchasing an additional 600 shares during the last quarter. Finally, Entropy Technologies LP lifted its holdings in shares of Tempus AI by 36.4% during the third quarter. Entropy Technologies LP now owns 147,040 shares of the company’s stock valued at $12,043,000 after purchasing an additional 39,262 shares during the last quarter. 24.22% of the stock is owned by institutional investors.
Recent Tempus AI Headlines
These are some of the TEM headlines that stood out recently:
- Positive Sentiment: The company extended its strategic collaboration with AstraZeneca. Separate investor coverage cited data agreements expected to generate $193 million over five years and oncology pricing changes expected to add $80 million in average selling price during 2027, supporting the longer-term growth case. AstraZeneca collaboration Investor takeaways
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, indicating confidence in Tempus’s outlook. HC Wainwright rating
- Neutral Sentiment: Several senior executives, including the CEO and CFO, sold shares. The filings say the sales covered tax withholding obligations on vested equity awards, making them less indicative of a change in confidence, though multiple insider sales may still draw investor attention. Insider sale report
Tempus AI Company Profile
Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.
Further Reading
- Five stocks we like better than Tempus AI
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
